Abingworth Bioventures
SelectiveLondon, X0Biotechnology, Pharmaceuticals, HealthcareLast fund filed November 2016
9 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Abingworth Bioventures VII LP | November 2016 | $400M | $240M | 16 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
9 partners are named across this firm’s filings, 9 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Shelley Chu | Selective | Biotech & pharma | 12 | 2 |
Classified sectors of Abingworth Bioventures’s own portfolio companies, based on 25 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Abingworth Bioventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Atlas Venture | 7 | Antares Therapeutics, IFM Cinque, IFM Continua, IFM Quattro, IFM Tre, Scorpion Therapeutics, Triana Biomedicines |
| Caduceus Capital | 2 | AVEDRO, Odyssey Therapeutics |
| Lightstone Ventures | 2 | GYNESONICS, HYDRA BIOSCIENCES |
| MPM BioVentures |
| David Leathers | Quiet | None listed | 0 | 0 |
| Genghis Lloyd-harris | Quiet | Biotech & pharma | 1 | 0 |
| James Abell | Quiet | None listed | 0 | 0 |
| Ken Haas | Quiet | Biotech & pharma, Digital health, Medical devices | 3 | 0 |
| Michael Bigham | Quiet | Biotech & pharma, Medical devices | 4 | 0 |
| Stephen Bunting | Quiet | None listed | 0 | 0 |
| Timothy Haines | Quiet | Biotech & pharma | 2 | 0 |
| Vincent Miles | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| CHIASMA, PROTEON THERAPEUTICS |
| Orbimed Asia Partners | 2 | AVEDRO, Odyssey Therapeutics |
| Orbimed New Horizons | 2 | AVEDRO, Odyssey Therapeutics |
| Orbimed Partners | 2 | AVEDRO, Odyssey Therapeutics |
| Third Rock Ventures | 2 | Abata Therapeutics, Triana Biomedicines |
| Sofinnova Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| The Column Group | 1 | EFFECTOR THERAPEUTICS |
| U.S Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| Vivo Capital | 1 | AVEDRO |
A shared board seat: a company where filings name a Abingworth Bioventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.